Stem Cell Clinic

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

By Global News Feed

REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines.

Read the original:
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

By Global News Feed

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company’s Chief Operating Officer (“COO”). Micek’s promotion reflects his role change from Interim COO of the Company since May, 2024

Read more:
Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

By Global News Feed

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows:

See the original post here:
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant…

By Global News Feed

SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic solid tumor cancers SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic solid tumor cancers

Continued here:
Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant...

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

By Global News Feed

BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the Jefferies Global Healthcare Conference, taking place in New York on June 3 - 5, 2025.

Read more here:
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

By Global News Feed

CLEVELAND, May 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Ph.D., Chief Executive Officer, and Madhav Vasanthavada, Ph.D., Chief Commercial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 11:40 a.m. Eastern Time.

See original here:
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

By Global News Feed

HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced the acceptance of three abstracts for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. The abstracts highlight Processa’s pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri), showcasing both preclinical and clinical advances.

See original here:
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla

By Global News Feed

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has become aware of unknown parties illegally retailing a nasal spray online, falsely claiming to be a PharmAla Biotech product and unlawfully using PharmAla logos and trademarks. PharmAla is issuing this warning in order to protect consumers and patients.

Original post:
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

By Global News Feed

Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl)

Visit link:
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

→←